Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 58, Issue 8, Pages 1872-1879
Publisher
Informa UK Limited
Online
2017-02-01
DOI
10.1080/10428194.2016.1263842
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
- (2016) P. G. Richardson et al. BLOOD
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Current strategies for treatment of relapsed/refractory multiple myeloma
- (2014) Jacob P Laubach et al. Expert Review of Hematology
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
- (2013) T. M. Herndon et al. CLINICAL CANCER RESEARCH
- Carfilzomib: a novel agent for multiple myeloma
- (2013) Kimberly Redic JOURNAL OF PHARMACY AND PHARMACOLOGY
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
- (2012) Elisa Gallerani et al. EUROPEAN JOURNAL OF CANCER
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
- (2012) Eric Sanchez et al. LEUKEMIA RESEARCH
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
- (2009) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
- (2008) Bruce D. Dorsey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More